- Home
- ATHR vs PBYI Comparison
ATHR vs PBYI Comparison
Compare ATHR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHR
- PBYI
- Stock Information
- Founded
- ATHR 2003
- PBYI 2010
- Country
- ATHR United States
- PBYI United States
- Employees
- ATHR N/A
- PBYI N/A
- Industry
- ATHR
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ATHR
- PBYI Health Care
- Exchange
- ATHR NYSE
- PBYI Nasdaq
- Market Cap
- ATHR 200.4M
- PBYI 167.3M
- IPO Year
- ATHR 2025
- PBYI N/A
- Fundamental
- Price
- ATHR $11.19
- PBYI $3.24
- Analyst Decision
- ATHR
- PBYI Strong Buy
- Analyst Count
- ATHR 0
- PBYI 1
- Target Price
- ATHR N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ATHR 53.0K
- PBYI 353.1K
- Earning Date
- ATHR 05-16-2025
- PBYI 07-31-2025
- Dividend Yield
- ATHR N/A
- PBYI N/A
- EPS Growth
- ATHR N/A
- PBYI 143.51
- EPS
- ATHR N/A
- PBYI 0.77
- Revenue
- ATHR $1,406,012.00
- PBYI $232,709,000.00
- Revenue This Year
- ATHR N/A
- PBYI N/A
- Revenue Next Year
- ATHR N/A
- PBYI N/A
- P/E Ratio
- ATHR N/A
- PBYI $4.14
- Revenue Growth
- ATHR N/A
- PBYI 2.68
- 52 Week Low
- ATHR $4.63
- PBYI $2.23
- 52 Week High
- ATHR $19.69
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- ATHR N/A
- PBYI 50.17
- Support Level
- ATHR N/A
- PBYI $3.38
- Resistance Level
- ATHR N/A
- PBYI $3.70
- Average True Range (ATR)
- ATHR 0.00
- PBYI 0.18
- MACD
- ATHR 0.00
- PBYI -0.03
- Stochastic Oscillator
- ATHR 0.00
- PBYI 35.82
About ATHR AETHER HOLDINGS INC
Aether Holdings Inc is an emerging financial technology platform company that offers proprietary research analytics, data and tools for both institutional and retail equity traders through flagship platform, SentimenTrader.com. Its platform currently provides coverage of U.S. equity and option securities, evaluating the equities and options markets and conducting assessments through analysts and technology daily.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.